Abstract
Alzheimers disease is the most common neurodegenerative disorder, clinically characterized by a noticeable cognitive decline defined by a loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living, and a diverse array of neuropsychiatric symptoms such as apathy, verbal and physical agitation, irritability, depression etc. Pharmacotherapy of Alzheimers disease has progressed in the past ten years from the use of psychotropic medications for sedation to the use of rational treatments aimed at neurotransmitter replacement. Only one class of medications has been extensively evaluated in clinical trials with patients with Alzheimers disease and is approved by the US Food and Drug Administration for Alzheimers disease treatment. These medications are cholinesterase inhibitors and have a significant, although modest, effect on the cognitive status of patients with Alzheimers disease.
Keywords: Alzheimer's disease, cholinesterases, cholinesterase inhibitors
Current Enzyme Inhibition
Title: Cholinesterases and Cholinesterase Inhibitors
Volume: 4 Issue: 4
Author(s): Sarka Stepankova and Karel Komers
Affiliation:
Keywords: Alzheimer's disease, cholinesterases, cholinesterase inhibitors
Abstract: Alzheimers disease is the most common neurodegenerative disorder, clinically characterized by a noticeable cognitive decline defined by a loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living, and a diverse array of neuropsychiatric symptoms such as apathy, verbal and physical agitation, irritability, depression etc. Pharmacotherapy of Alzheimers disease has progressed in the past ten years from the use of psychotropic medications for sedation to the use of rational treatments aimed at neurotransmitter replacement. Only one class of medications has been extensively evaluated in clinical trials with patients with Alzheimers disease and is approved by the US Food and Drug Administration for Alzheimers disease treatment. These medications are cholinesterase inhibitors and have a significant, although modest, effect on the cognitive status of patients with Alzheimers disease.
Export Options
About this article
Cite this article as:
Stepankova Sarka and Komers Karel, Cholinesterases and Cholinesterase Inhibitors, Current Enzyme Inhibition 2008; 4 (4) . https://dx.doi.org/10.2174/157340808786733631
DOI https://dx.doi.org/10.2174/157340808786733631 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Iron and Iron Chelators: A Review on Potential Effects on Skin Aging
Current Aging Science Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Probenecid: An Emerging Tool for Neuroprotection
CNS & Neurological Disorders - Drug Targets Prion-like Mechanisms in Alzheimer's Disease
Current Alzheimer Research Meet Our Regional Editor
CNS & Neurological Disorders - Drug Targets GPCR Drug Discovery: Novel Ligands for CNS Receptors
Recent Patents on CNS Drug Discovery (Discontinued) Potential of Submergedly Cultivated Mycelia of Ganoderma spp. as Antioxidant and Antimicrobial Agents
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Local Melatonin Regulates Inflammation Resolution: A Common Factor in Neurodegenerative, Psychiatric and Systemic Inflammatory Disorders
CNS & Neurological Disorders - Drug Targets Experimental and Clinical Advances in Immunotherapy Strategies for Spinal Cord Injury Target on MAIs and Their Receptors
Current Pharmaceutical Design Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
Current Pharmaceutical Design Preface
Current Pharmaceutical Design Peptides and their Metal Complexes in Neurodegenerative Diseases: from Structural Studies to Nanomedicine Prospects
Current Medicinal Chemistry Tetracyclines and Neuromuscular Disorders
Current Neuropharmacology The Neurotrophic and Antiangiogenic Functions of PEDF: A Reflection of its Variable Phosphorylation States
Current Genomics Position Based Nucleotide Analysis of miR168 Family in Higher Plants and its Targets in Mammalian Transcripts
MicroRNA Exploring Nitrostyrene as a Scaffold for a New Class a of Monoamine Oxidase Inhibitors
Letters in Drug Design & Discovery Neurogenesis and Stroke
CNS & Neurological Disorders - Drug Targets Development of Radioligands for In Vivo Imaging of Type 1 Cannabinoid Receptors (CB1) in Human Brain
Current Pharmaceutical Design